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Several lines of evidence implicate BDNF in the pathogenesis of stress-induced depression and the delayed eﬃcacy of antidepres-
sant drugs. Antidepressant-induced upregulation of BDNF signaling is thought to promote adaptive neuronal plasticity through
eﬀects on gene expression, but the eﬀector genes downstream of BDNF has not been identiﬁed. Local infusion of BDNF into the
dentate gyrus induces a long-term potentiation (BDNF-LTP) of synaptic transmission that requires upregulation of the imme-
diate early gene Arc. Recently, we identiﬁed ﬁve genes (neuritin, Narp, TIEG1, Carp, and Arl4d) that are coupregulated with Arc
duringBDNF-LTP.Here,weexamined theexpressionofthesegenesinthedentategyrus,hippocampusproper,andprefrontalcor-
tex after antidepressant treatment. We show that chronic, but not acute, ﬂuoxetine administration leads to upregulation of these
BDNF-LTP-associated genes in a brain region-speciﬁc pattern. These ﬁndings link chronic eﬀects of antidepressant treatment to
molecular mechanisms underlying BDNF-induced synaptic plasticity.
Copyright © 2007 Maria Nordheim Alme et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Stable activity-dependent changes in synaptic eﬃcacy, as
seen during long-term potentiation (LTP) and long-term
depression (LTD), require new gene expression. Persistent
changes of this kind are thought to underlie long-term adap-
tive responses in behaviour, including memory formation,
motivation, mood, and pain control. Maintenance of LTP
induced by high-frequency stimulation (HFS) of excitatory
glutamatergic synapses is typically divided into a transient
early phase and a persistent late phase [1]. Development of
late LTP requires gene transcription and protein synthesis,
a process referred to as LTP consolidation. One of the ma-
jor regulators of LTP consolidation is the secretory polypep-
tide brain-derived neurotrophic factor (BDNF) [2, 3]. BDNF
is released postsynaptically from or near glutamate synapses
in response to HFS and signals through TrkB receptor ty-
rosine kinases located pre- and post-synaptically [4–7]. Ex-
ogenous application of BDNF induces a long-term potentia-
tion (BDNF-LTP) that mimics the late phase of LTP [8, 9]. In
the dentate gyrus of adult rats in vivo, BDNF-LTP induction
requires extracellular signal-regulated kinase activation, new
genetranscription,andisoccludedbypriorexpressionoflate
LTP [9, 10] BDNF-LTP is associated with rapid upregulation
and dendritic transport of mRNA encoded by the immediate
earlygene,activity-regulatedcytoskeleton-associatedprotein
(Arc, aka Arg3.1). Furthermore, Arc synthesis is necessary
for the consolidation of BDNF-LTP and HFS-induced LTP
[11, 12].
Several lines of evidence from human and animal stud-
ies implicate BDNF in the pathogenesis of stress-induced
depression and the delayed eﬃcacy of antidepressant drugs
[13–16]. Rodent studies suggest that stress exposure reduces
BDNFexpressionandTrkBsignalinginthehippocampalfor-
mation and neocortex, while antidepressant treatment in-
creases TrkB signaling and counteracts the behavioral eﬀects
of stress [16–20]. It has been suggested that antidepressant-
induced upregulation of BDNF signaling promotes activity-
dependent synaptic plasticity, synaptic reorganization, and
neuronal survival [14–21]. Such adaptive responses require2 Neural Plasticity
new gene expression, but the eﬀector genes downstream of
BDNF has not been identiﬁed.
In a recent microarray screen, we identiﬁed ﬁve genes
that are strongly coupregulated with Arc mRNA during
both BDNF-LTP and HFS-LTP in the dentate gyrus [22].
These genes are neuritin, neuronal activity-regulated pen-
traxin (Narp), TGFβ-inducible early gene (TIEG1), cal-
cium/calmodulin kinase-related peptide (Carp), and ADP-
ribosylation factor-like protein-4 (Arl4d). Brieﬂy, neuritin,
also known as candidate platicity gene 15 (CPG15), is an im-
mediate early gene which encodes a small, extracellular gly-
cosylphosphatidylinositol (GPI)-anchored protein impor-
tant for dendritic outgrowth and maturation [23, 24]. Narp
isanimmediateearlygeneinthepentraxinfamilyofsecreted
lectins. Narp forms pentraxin assemblies that contribute to
both activity-dependent and activity-independent excitatory
synaptogenesis [25]. TIEG1, a member of the speciﬁcity
protein/Kruppel-like factor (SP/KLF) family of zinc-ﬁnger
transcription factors [26, 27], enhances TGF-β-dependent
gene expression [28]. Carp, also known as ANIA-4 [29],
contains the auto-inhibitory domain of CaMK-IV, suggest-
ing that it may modulate CaM-kinase activity [30]. ADP-
ribosylation factors (ARFs) and ARF-like proteins (ARLs)
belong to the Ras superfamily of small GTP-binding proteins
(GTPases)involvedbroadlyinintratracellulartraﬃckingand
signaling [30, 32]. The rat gene Arl4d is a predicted sequence
from the human gene ARL4D (former name ARF4L); new
nomenclature described in [33].
Because of a possible link between BDNF-mediated ef-
fects of antidepressant treatment and synaptic plasticity,
these BDNF-LTP coupled genes are all attractive as possi-
ble eﬀectors of chronic antidepressant treatment. Here, we
demonstrate brain region-speciﬁc upregulation of BDNF-
LTP associated genes (neuritin, Narp, TIEG1 Arl4d, Carp,
and Arc) after chronic, but not acute, ﬂuoxetine adminis-
tration. These ﬁndings suggest that antidepressant treatment
promotes gene expression responses linked to BDNF signal-
ing and long-term synaptic plasticity.
2. EXPERIMENTAL PROCEDURES
These experiments were approved by the Norwegian Com-
mittee for Animal Research in accordance with European
Community Council Directives.
2.1. Animals
Adult male Spraque-Dawley rats (Mølleg˚ ards Avlslaborato-
rium, Denmark) weighing 190–300g were housed in groups
of four in a climate controlled room of constant temper-
ature (21 ± 1◦C) and humidity. They were kept on a 12-
hour light/dark cycle (lights on at 7:00 AM, lights oﬀ at 7:00
PM). Food and water were available ad libitum. For the acute
treatments, rats received a single intraperitoneal (IP) injec-
tion of ﬂuoxetine (10mg/kg) or saline (0.9% NaCl) at 10:00
AM on the day of the experiment. For the chronic treat-
ments, rats received daily (at 10:00 AM) IP injections of ﬂu-
oxetine (10mg/kg/day) or saline (0.9% NaCl) for 21 days.
Two hours after the last injection the rats were anesthetized
(urethane, 25mg/kg IP), decapitated, and the brain was re-
moved. The 2-hour time point was chosen because of pre-
vious evidence that translation factors are modulated at this
time and because the mRNAs under study are all induced
within 1–2 hours of BDNF infusion into the dentate gyrus
[22, 34]. The dentate gyrus, hippocampus proper, and pre-
frontal cortex were rapidly dissected on ice and kept cold by
repeated rinses in ice-cold artiﬁcial cerebrospinalﬂuid, ACSF
(in mM): NaHCO3 (26), NaCl (124), KCl (3), MgSO4 (1.3),
NaH2PO4 (1.25), glucose (10), pH (7.4). The prefrontal cor-
tex was removed ﬁrst. The dentate gyrus and the hippocam-
pus proper were separated by unfolding the dentate gyrus
from the hippocampus, leaving the CA1 and CA3 regions
exposed. The tissue was rapidly frozen on a dry-ice/ethanol
slurry and stored at −80◦C.
2.2. Poly(A)RNAandcDNApreparation
Poly(A)RNAwasisolatedusingtheDynabeadsmRNAdirect
kit (Dynal, Oslo, Norway) according to the manufacturer’s
protocol. Minor modiﬁcations were that 70μLm a g n e t i c
beads were used per sample and that the isolated poly(A)
RNAfractionwaselutedin3×30μLel utionbuﬀer.Theyield
and quality of the poly(A) RNA were determined by mea-
suringtheabsorbanceat260/280nm.60ngpoly(A)RNAwas
reversed transcribed using the Superscript First-Strand Syn-
thesis Kit (Invitrogen). The cDNA was diluted 20-fold.
2.3. Semiquantitativereal-timePCRand
normalizationstrategies
Semiquantitative real-time PCR was performed on an iCy-
cler (Bio-Rad) using cDNA from individual animals and the
iQ SYBR Green Supermix. Five μL cDNA was added to the
PCR reaction mix to yield a total of 25μL. PCR quantiﬁca-
tion was performed in triplicate and the ﬂuorescence signal
was quantiﬁed by the second derivative maximum method
2−ΔCt,w h e r eΔCt = Ctgene − Cthousekeeping gene for each ani-
mal using the iCycler iQ real-time detection system software.
Student’s t-test was used for the statistical analyses. Primers
used are given in Table 1.
The determination of an appropriate housekeeping gene
is discussed in several papers [35]. Five housekeeping genes
havebeenanalyzedforthispurpose:Gadph,tubulin,Arp,cy-
clopholine, and polyubiquitine. gNorm was used for stabil-
ity analyses and polyubiquitine was chosen as the preferred
housekeeping gene. Primer sequences in 5  to 3  direction
and annealing temperatures are given in Table 1.
3. RESULTS
3.1. Chronicﬂuoxetinetreatmentleadstobrain
region-speciﬁcupregulationofgenes
coupledtoBDNF-LTP
Rats received acute (1 day) or chronic (21 days) treat-
ment with the selective serotonin reuptake inhibitor, ﬂuoxe-
tine. Semiquantitative real-time PCR was used to determine
changes in the expression of BDNF-LTP coupled genes inMaria Nordheim Alme et al. 3
Table 1: Primer sequences, annealing temperature, and accession numbers for the analyzed genes.
Gene Primer sequence Ann temp. (C◦)A c c n u m b e r
Narp Fw: GGCAAGATCAAGAAGACGTTG 58 P97738
Bw: TCCAGGTGATGCAGATATGGT
Carp Fw: CAGGCAACCCTACCAGCATTT 58 AF030089
Bw: TAACACTCCAACAGGCAGCA
Arl4l Fw: CTTCCCTTCTTTACCGCCTCA 58 XM 220933
Bw: ACCCCCAACATCCCACACTT
TIEG1 Fw: TAGTGTCTCAGTGCTCCGTCTG 62 NP 112397
Bw: TGTGCTCCCTCTTTGGACTTTTC
Neuritin Fw: GGGACTTAAGTTGAACGGCA 56 NM 053346
Bw: ACCCAGCTTGAGCAAACAGT
BDNF exon-III Fw: TGCGAGTATTACCTCCGCCAT 60 X67107
Bw: AGGATGGTCATCACTCTTCTC
BDNF exon-V Fw: TGGGACTCTGGAGAGCGTGAATGG 62 BC087634
Bw: CGGGACTTTCTCCAGGACTGTGAC
Cyclopholine Fw: AGCACTGGGGAGAAAGGATT 60 BC059141
Bw: GATGCCAGGACCTGTATGCT
Polyubiqutine Fw: GGCAAGACCATCACCCTAGA 60 BC070919
Bw: GCAGGGTTGACTCTTTCTGG
Gapdh Fw: CTGAGAATGGGAAGCTGGTCATC 62 DQ403053
Bw: CAGTGGATGCAGGGATGATGTTC
Tubulin Fw: GGGAGCTCTACTGCCTGGAACATG 62 NM001007004
Bw: GGAGACAATTTGGCTGATGAGGCG
Arp Fw: CGACCTGGAAGTCCAACTAC 60 NM022402
Bw: ATCTGCTGCATCTGCTTG
Arc Fw: CCCAGTCTGTGGCTTTTGTCA 60 NM019361
Bw: GTGTCAGCCCCAGCTCAATC
microdissected prefrontal cortex, hippocampus proper, and
dentate gyrus. These brain regions were selected for analy-
sis because of their role in memory loss and other cognitive
features of aﬀective disorders, and because chronic antide-
pressant treatment is thought to upregulate BDNF function
in these regions [13].
In prefrontal cortex (Figure 1(a)), mRNA levels for Narp
and TIEG1 were signiﬁcantly upregulated more than 9-fold
after chronic ﬂuoxetine administration, relative to saline
control.Neuritin,Carp,andArl4dweresigniﬁcantlyelevated
morethan2-foldinresponsetochronicﬂuoxetinetreatment.
Incontrast,noneofthemRNAsexaminedshowedalteredex-
pression following acute ﬂuoxetine treatment.
Inhippocampusproper(Figure 1(b)),TIEG1mRNAlev-
els were elevated 7-fold, Narp was elevated 4-fold, and Arc
was elevated 3-fold following chronic antidepressant treat-
ment. In the acute ﬂuoxetine group, Narp expression was re-
duced while expression of the remaining BDNF-LTP linked
genes was unchanged.
In the dentate gyrus (Figure 1(c)), neuritin and TIEG1
were signiﬁcantly upregulated 2-fold in the chronic ﬂuoxe-
tinegroup.Acuteﬂuoxetinetreatmentproducedasigniﬁcant
decline in TIEG1 and Carp mRNA expression.
3.2. Chronicﬂuoxetinetreatmentleadstobrain
region-speciﬁcregulationofBDNF
exon-IIIspeciﬁcmRNA
The BDNF gene consists of four 5  noncoding exons (I-
IV) each with a separate promotor and one 3  exon (exon-
V) encoding the mature BDNF protein. The exon-III and
IV BDNF promoters are regulated as immediate early genes
[36, 37]. Previous work showed that BDNF-LTP is associ-
ated with rapid upregulation of exon-III speciﬁc and exon-V
(total) BDNF mRNA [22]. We examined expression of these
transcripts in order to further compare the eﬀects of ﬂuoxe-
tine treatment with that of BDNF infusion.
In prefrontal cortex (Figure 2(a)), exon-III and exon-V
BDNF mRNA levels were signiﬁcantly elevated about 3-and
2-fold, respectively, after chronic antidepressant treatment.
No signiﬁcant changes in prefrontal cortex BDNF expression
were observed following acute treatment. In hippocampus4 Neural Plasticity
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Figure 1: Chronic ﬂuoxetine administration leads to brain region-speciﬁc upregulation of LTP-associated genes. Changes in mRNA expres-
sion following ﬂuoxetine treatment are expressed as fold change relative to the saline control group. (a) Prefrontal cortex, (b) hippocampus
proper, (c) dentate gyrus. N = 7 ﬂuoxetine chronic, n = 8 NaCl chronic, n = 5 ﬂuoxetine acute, n = 4 NaCl acute (except neuritin chronic
NaCl in DG, n = 7). ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 from Student’s t-test.
proper, chronic ﬂuoxetine administration led to a 2.5-fold
increase in exon-III expression, but no signiﬁcant change
in exon-V expression (Figure 2(b)). In contrast, acute treat-
ment produced a signiﬁcant decrease in exon-III BDNF
mRNA levels relative to saline-injected controls. In the den-
tate gyrus, ﬂuoxetine treatment had no signiﬁcant eﬀects on
exon-III or exon-V BDNF mRNA expression at the times ex-
amined (Figure 2(c)).Maria Nordheim Alme et al. 5
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Figure 2: Brain region-speciﬁc upregulation of BDNF exon-III speciﬁc mRNA in chronic ﬂuoxetine-treated rats. (a) Prefrontal cortex, (b)
hippocampus proper, (c) dentate gyrus. N = 7 ﬂuoxetine chronic, n = 8 NaCl chronic, n = 5 ﬂuoxetine acute, n = 4N a C la c u t e .∗P<. 05,
∗∗P<. 01 Student’s t-test.6 Neural Plasticity
4. DISCUSSION
This study demonstrates that chronic, but not acute, ad-
ministration of ﬂuoxetine leads to brain-region speciﬁc up-
regulation of genes associated with BDNF-induced LTP and
HFS-induced LTP in the adult brain. This ﬁnding supports
the idea that chronically administered antidepressants pro-
mote BDNF-induced gene expression and synaptic plastic-
ity in multiple brain regions. The study also identiﬁes neu-
ritin, Narp, TIEG1, Carp, and Arl4d as candidate eﬀectors of
chronic ﬂuoxetine treatment.
These ﬁve genes were originally identiﬁed in a microar-
ray screen for mRNAs that are co-upregulated with Arc dur-
ing long-term synaptic plasticity. Using in situ hybridization,
Wibrand et al. [22]c o n ﬁ r m e de n h a n c e dm R N Ae x p r e s s i o n
for all genes in dentate granule cells following both BDNF-
LTP and HFS-LTP. The kinetics of mRNA expression was
rapid (40 minutes post-HFS) and sustained (3 hours post-
BDNF). In chronic ﬂuoxetine-treated rats, all genes were up-
regulated in at least one of three brain regions studied (pre-
frontal cortex, dentate gyrus, and hippocampus proper), and
each brain region exhibited a unique gene expression pat-
t e r n .I nt h ep r e f r o n t a lc o r t e x ,n e u r i t i n ,N a r p ,T I E G 1 ,C a r p ,
and Arl4d were all strongly upregulated. In the hippocam-
pus proper, neuritin, Narp, TIEG1, and Arc were upregu-
lated. In the dentate gyrus, only neuritin and TIEG1 were
upregulated after three weeks of ﬂuoxetine treatment. The
basis of the regional eﬀects on gene expression is unclear at
present. Regional diﬀerences in the time course of TrkB sig-
naling is one possible explanation. A single injection of ﬂu-
oxetine, although suﬃcient to activate TrkB receptors [20],
does not induce enhanced expression of BDNF-LTP-coupled
genes. Repetitive treatment may produce regional patterns
of BDNF-TrkB signaling and gene expression that are not
seen following acute treatment. Regional gene expression
may also be strongly gated by serotonin and by ﬂuoxetine-
induced modulation of trophic factors such as activin [38].
Furtherstudiesareneeded toresolvethedetailedtime course
of gene expression during chronic antidepressant treatment
as well as the duration of gene expression following cessation
of treatment.
Although acute ﬂuoxetine did not enhance gene expres-
sion in any of the brain regions studied, Narp expression was
signiﬁcantlydecreasedinthehippocampus,whileTIEG1and
Carp expression was decreased in the dentate gyrus. The dis-
cussion below concentrates on responses speciﬁc to chronic
antidepressant regimens, yet it is important to bear in mind
that acute eﬀects may shed light on how the late eﬀects de-
velop.Forexample,rapidtranslationanddegradationofpre-
existing mRNA in response to the ﬁrst exposure to ﬂuox-
etine may be followed by a slow wave of new gene expres-
sion.
TIEG1 was the only gene upregulated in all brain regions
analyzed. TIEG1 is an immediate early gene belonging to the
speciﬁcityprotein/Kruppel-likefactorfamilyoftranscription
factors.ThesetranscriptionfactorsbindtoGC-richelements
in the promoter region of target genes and are known to
regulate a large number of genes involved in cell growth,
diﬀerentiation and apoptosis [26, 39, 40]. TIEG1 is rapidly
induced by TGF-β, a family of growth factors aﬀecting gene
expression and cellular functions primarily through activa-
tion of the Smad signaling pathways. TIEG1 potentiates the
induction of TGF-β/Smad-regulated genes and overexpres-
sion of TIEG1 mimics the physiological eﬀects of TGF-β in
many cell types [28, 41]. In Aplysia, TGF-β induces a long-
term increase in sensory neuron excitability and enhances
transmission at sensorimotor synapses [42]. The pattern of
upregulation of TIEG1 in the present study suggests that
TGF-β signaling is widely upregulated following chronic ﬂu-
oxetine treatment. Interestingly, phosphorylation of Smad2,
one of the major mediators of TGF-β signalling, is also el-
evated following ﬂuoxetine treatment [38]. In contrast to
TIEG1, Smad2 phosphorylation is observed after both acute
andchronic(3week)treatmentandonlyinthefrontalcortex
(not in hippocampus).
Narp and neuritin are suggested to play important roles
in neuronal development and synapse formation. Narp in-
duces AMPA receptor clustering and it has been shown
that overexpression of Narp increases excitatory, but not in-
hibitory, synapse formation [43–45]. Neuritin is known to
play important roles in synapse formation and maturation
during development by promoting dendritic and axonal ar-
borgrowth[23,24,46,47].Neuritinisimplicatedinactivity-
dependent developmental plasticity in the cortex and tran-
scription of neuritin in primary cortical neuron cultures is
NMDA receptor-dependent and requires convergent activa-
tion of the CaMK and MAPK pathways [48, 49]. While the
function of NARP and neuritin in adulthood is still little
understood, upregulation of these genes implies eﬀects on
AMPA receptor clustering and synapse growth or reorgani-
zation.
Carp is one of several splice variants from the DCAMKL
gene and contains 3 of its 15 exons. Carp lacks catalytic ac-
tivity and is structurally similar to the autoinhibitory do-
main of CaMK-IV, a key regulator of calcium-induced gene
expression [50, 51]. Previous studies have shown upregula-
tion of Carp following kainic acid-induce seizures and it has
been suggested that Carp is only expressed during cytotoxic
conditions [30, 51]. This is in contrast to the results from
the present study, where we show physiological expression
of Carp in saline-injected controls and upregulation of ex-
pression in the prefrontalcortex following chronic ﬂuoxetine
treatment.
ADP-ribosylation factors (ARFs) and ARF-like proteins
(ARLs) belong to the Ras superfamily of small GTP-binding
proteins [31, 32]. The rat gene Arl4d is a predicted sequence
from the humane gene ARL4D, a member of a subgroup of
ARL-proteins characterized by the presence of a nuclear lo-
calization signal and rapid nucleotide exchange activity [52].
ARL GTPases have been suggested to serve as adaptors for
cargoes lacking nuclear localization signals [53, 54]. In ad-
dition, Arl4d protein distributes to the plasma membrane
when bound to GTP and to endosomes when bound to GDP,
suggesting a role in transport between these compartments
[54]. In situ hybridization shows that Arl4d mRNA is ex-
pressed in distinct nuclear punta in dentate granule cells
[22]; a pattern reminiscent of nuclear structures such as PcG
domains and coiled bodies. Chronic ﬂuoxetine treatmentMaria Nordheim Alme et al. 7
increased the level of Arl4d mRNA about 2-fold in the
prefrontal cortex, but did not change its expression in the
hippocampus or dentate gyrus.
Arc mRNA was signiﬁcantly upregulated 3-fold in the
hippocampus proper, but was unchanged in the dentate
gyrus. There was also a tendency for enhanced Arc expres-
sion in the prefrontal cortex (2.5-fold increase), though the
interanimal variability was great. The present results ap-
pear consistent with earlier studies reporting enhanced Arc
mRNA expression in the frontal cortex and CA1 region,
but not in CA3 region or dentate gyrus, following treat-
ment with the SSRI paroxetine either alone or in combina-
tion with antagonists of presynaptic 5-HT1A receptors [55].
Chronic treatment with the triple monoamine reuptake in-
hibitor, tesofensine, similarly upregulated Arc in the CA1 re-
gion,butnotindentategyrus[56].Althoughthetimecourse
of gene induction needs to be resolved in ﬁner detail, it is ev-
ident that Arc and the other BDNF-LTP genes are not always
coexpressed.
Antidepressant-induced upregulation of total (exon-V)
BDNF mRNA expression has been observed in many stud-
ies, but the regional expression pattern varies with the an-
tidepressant used and treatment paradigm, with some stud-
ies reporting no eﬀect (reviewed in [15, 16]). Recent stud-
ies suggest a similar variability in the eﬀects of ﬂuoxetine
on exon-speciﬁc promoters. Dwivedi et al. [57] showed that
chronic ﬂuoxetine treatment (3 weeks of daily IP injection)
had no eﬀect on exon-III containing BDNF transcripts in the
frontalcortexandhippocampus,yetincreasedexon-IIBDNF
mRNA levels in hippocampus. Another study reported up-
regulation of exon-I, but not exon-III, mRNA in the den-
tate gyrus and hippocampus after 3 weeks of ﬂuoxetine ad-
ministration [58]. Under the present conditions, total BDNF
and BDNF exon-III were upregulated in the prefrontal cor-
tex, while no signiﬁcant eﬀects were observed in the dentate
gyrus. In hippocampus proper BDNF exon-III mRNA was
upregulated, while no signiﬁcant regulation of total BDNF
was seen. We can only speculate on the reason for this dis-
crepancy,whichcouldreﬂectalargerfractionalchangeinthe
expression of low abundance exon-III transcripts, or down-
regulation of transcription from other exon-speciﬁc promo-
tors [58]. A similar strong upregulation of exon-III contain-
ing transcripts was previously observed following BDNF-
LTP [22]. It should be emphasized, however, that the phys-
iological impact of this BDNF mRNA upregulation remains
unclear. Is it required for synaptic plasticity or does it re-
ﬂect a delayed, compensatory resynthesis following BDNF
release?
Several events associated with BDNF-LTP in the den-
tate gyrus are induced by chronic antidepressant treatment.
Chronic antidepressant treatment leads to enhanced TrkB
signaling, CREB activation [20, 59–61], and transcription
of genes associated with BDNF-induced LTP. In addition
to regulating transcription, BDNF modulates protein syn-
thesis at the level of mRNA translation [12]. Thus, BDNF-
LTP is associated with rapid and transient phosphoryla-
tion of two translation factors critical in controlling global
translation initiation and elongation rates, eukaryotic initia-
tion factor 4E (eIF4E), and elongation factor-2 (eEF2) [62].
Chronic ﬂuoxetine-treatment similarly modulates eIF4E and
eEF2 activity in the dentate gyrus [34]. Furthermore, acute
infusion of BDNF into the dentate gyrus has behavioral
antidepressant-like eﬀects in rats [63]. Taken together, these
data raises the possibility that antidepressants could work at
least in part through molecular mechanisms similar to those
seen during BDNF-LTP.
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